Summary
Gland Pharma shares surged 12% after reporting a 47% year-on-year profit increase and 20% revenue growth in Q1FY27. Despite strong performance, Elara Securities downgraded the stock to 'Accumulate' from 'Buy' due to limited near-term upside after a significant rally.